Xylitol dental wipes to reduce infection risk in childhood leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether using xylitol dental wipes can lower the risk of bloodstream infections in children with acute myeloid leukemia (AML) who are receiving chemotherapy. If you or your child have AML and will have at least two cycles of chemo that include cytarabine, this study may help reduce infection risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 25 years old.
- You have acute myeloid leukemia (AML) that is either new or has come back.
- You are scheduled to receive at least two rounds of chemotherapy that includes the drug cytarabine and is expected to cause very low white blood cell counts for 7 days or more.
- You have at least one tooth that has come through the gums.
- You agree not to use any other xylitol products (like gum or toothpaste) during the study.
- You are not allergic to xylitol, grapes, or grape flavoring.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
This trial tests whether an antibiotic called dalbavancin, given to prevent bacterial infections during chemotherapy-induced low white blood cell counts, is safe and works in children and young adults with certain types of leukemia. It may help reduce the risk of serious infections during treatment.
This study tests a new way to monitor and treat AML in children and young adults after their first chemotherapy. It aims to improve outcomes by closely tracking the disease and adjusting treatment as needed.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.